FindTrial
Sign In

DVS-233 SR

DRUG10 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

DepressionDepressive DisorderHot FlashesMajor Depressive DisorderMenopauseSleep DisordersVasomotor Symptoms

Phase 3

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
CompletedNCT00063206
Wyeth is now a wholly owned subsidiary of PfizerMajor Depressive Disorder
End: 2004-05-31Updated: 2009-08-19
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
CompletedNCT00072774
Wyeth is now a wholly owned subsidiary of PfizerMajor Depressive Disorder
End: 2004-11-30Updated: 2009-08-19
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
CompletedNCT00073762
Wyeth is now a wholly owned subsidiary of PfizerMajor Depressive Disorder
End: 2004-09-30Updated: 2009-08-19
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
CompletedNCT00075257
Wyeth is now a wholly owned subsidiary of PfizerMajor Depressive Disorder
End: 2005-08-31Updated: 2009-08-19
Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder
CompletedNCT00087737
Wyeth is now a wholly owned subsidiary of PfizerMajor Depressive Disorder
End: 2005-05-31Updated: 2009-08-19
Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder
CompletedNCT00090649
Wyeth is now a wholly owned subsidiary of PfizerMajor Depressive Disorder
End: 2005-03-31Updated: 2009-08-19
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder
CompletedNCT00092911
Wyeth is now a wholly owned subsidiary of PfizerDepression, Depressive Disorder, Major Depressive Disorder
End: 2005-05-31Updated: 2009-08-19
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
CompletedNCT00256685
Wyeth is now a wholly owned subsidiary of PfizerHot Flashes, Menopause, Sleep Disorders
Start: 2004-09-30End: 2005-07-31Target: 568Updated: 2006-05-19
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
CompletedNCT00421031
Wyeth is now a wholly owned subsidiary of PfizerVasomotor Symptoms
Start: 2003-12-31End: 2004-04-30Target: 540Updated: 2007-01-11

Unknown Phase

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder
CompletedNCT00242229
Wyeth is now a wholly owned subsidiary of PfizerMajor Depressive Disorder
Start: 2004-10-31End: 2005-10-31Updated: 2009-08-19

Related Papers

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials
Journal of Clinical Psychopharmacology2021-06-291 citations
Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
2016-01-133 citations
A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d
The Primary Care Companion For CNS Disorders2015-06-0411 citations
Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.
2015-03-267 citations
An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder
The Primary Care Companion For CNS Disorders2015-02-26
Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
2008-01-01121 citations
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
2007-11-0147 citations